Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 2/20 | 0.68 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | ACKR3 | P25106 | 2/20 | 0.42 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | PDE6D | O43924 | 1/20 | 0.41 |
| ▸ | REN | P00797 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | CCR3 | P51677 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3702941 | 0.85 | NAMPT (0.61) | NAMPTHPGDKMT2AGAAPDE6D | |
| SCHEMBL3710417 | 0.83 | NAMPT (0.58) | NAMPTHPGDGAAPDE6DPOLB | |
| SCHEMBL3699732 | 0.81 | NAMPT (1.00) | NAMPT | |
| SCHEMBL10466773 | 0.71 | CNR2 (0.54) | NAMPTHPGDALDH1A1GAAREN | |
| SCHEMBL5332700 | 0.71 | TSHR (0.56) | NAMPTHPGDKMT2AALDH1A1ACKR3 | |
| SCHEMBL28805745 | 0.68 | CHRM2 (0.66) | ALDH1A1LMNAPOLB | |
| SCHEMBL8328142 | 0.68 | HDAC1 (0.47) | NAMPTALDH1A1ACKR3TMEM97SIGMAR1 | |
| SCHEMBL27719387 | 0.67 | TMEM97 (0.60) | NAMPTKMT2AACKR3TMEM97SIGMAR1 | |
| SCHEMBL23607906 | 0.67 | HDAC1 (0.44) | KMT2AALDH1A1ACKR3TMEM97SIGMAR1 | |
| SCHEMBL8325252 | 0.67 | HDAC1 (0.46) | ALDH1A1ACKR3TMEM97SIGMAR1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9302989-B2 | NAMPT and rock inhibitors | ABBVIE INC. (US) | 2016-04-05 | — | — | US | disclosed |
| US-20120122842-A1 | NAMPT AND ROCK INHIBITORS | ABBOTT LABORATORIES (US) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122842-A1 | NAMPT AND ROCK INHIBITORS | NAMPT, NNMT, NME2 | NAMPT 1/4885HPGD 132/4885KMT2A 2025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.